Release Date: 04-Oct-2021
FDA has granted LP-184 Orphan Drug Designation as a new treatment of glioblastoma multiforme (GBM) and other malignant gliomas, which follows the recent announcement of the approval of the drug to be used for pancreatic cancer treatment. Lantern Pharma uses artificial intelligence called RADR that helps to find biomarker signatures identifying patients most likely to respond to its genome-targeted therapeutics.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S and it also gives several benefits, like tax credits for qualified clinical trials, potential seven years of market exclusivity after approval and exemption from user fees.
LP-184 drug targets cancers, including GBM, which is a rare disease with an overall 5-year survival rate of 5%, as well as pancreatic cancer. This drug is a small molecule candidate that damages DNA in cancer cells that over-express biomarkers or harbor mutations in DNA repair pathways.